Therefore, it may be speculated that sodium channel blockers, particularly Nav1.6 and Nav1.7 α subunit-specific blockers, have the potential to participate in the prevention and treatment of prostate cancer. The gene discussed is SCN9A; the disease is Familial prostate cancer.